Linoleoyl ethanolamide_product_DataBase

Bioactivity	Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time[1][2].
Invitro	Linoleoyl ethanolamide competitively inhibits the hydrolysis of anandamide and may be involved in the regulation of food intake by selective prolongation of feeding latency and post-meal interval[3].
In Vivo	Linoleoyl ethanolamide (0.1 mg-0.2 mg; challenged by painting the inner and outer surfaces of both sides of their ears) suppresses DNFB-induced ear swelling in BALB/c mice[3].
Name	Linoleoyl ethanolamide
CAS	68171-52-8
Formula	C20H37NO2
Molar Mass	323.51
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Wang X, et al. X. Synthesis of linoleoyl ethanolamide. J Oleo Sci. 2013;62(6):427-433. [2]. Lin S, et al. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem. 1998;41(27):5353-5361.

PeptideDB